At Belenos Biosciences Inc., we believe that clinical remission should be the standard—not the exception—for treating chronic inflammatory diseases like COPD, asthma and atopic dermatitis. Our bispecific therapeutics are designed to target proven disease pathways, with the goal of delivering meaningful, lasting outcomes for patients. With a focus on innovation and speed, we are advancing our pipeline with urgency to bring next-generation treatments to those who need them most. An Orbimed company
